Dhuwit awis saben siji saham phathompharma.com (PHAT)

Lambang korporat lan logo Phathom (PHAT)

Phathom Pharmaceuticals maintains its leadership in treating gastrointestinal pathologies thanks to its proprietary drug Voquezna. The change in cash position per share clearly demonstrates the liquidity of the base, where the 2.27 indicator expresses the state of the metric. The company is currently scaling distribution among gastroenterologists, relying on prescription drug sales through pharmacy chains and the US health insurance system.

phathompharma.com (PHAT) - Dana dhuwit saben saham saka 04.07.2022 nganti 20.11.2026

Rincian metrik komprehensif lan analitis phathompharma.com (PHAT)

- rega pasar lan target rega analis:
- rincian posisi dhuwit lan arus kas:
Analisis komprehensif perusahaan:Phathom - PHAT
Barang unggulan Phathom Pharmaceuticals

Analyzing the current liquidity per share confirms the status of Phathom Pharmaceuticals (PHAT) as a resilient player in the non-cyclical gastroenterology segment. This indicator reflects the actual volume of free cash flow per share, where growth signals financial autonomy and stagnation indicates a risk of underinvestment in drug development, which ultimately determines the issuer's overall strength.